Chargement en cours...
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis
IMPORTANCE: The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer. However, resection rates of metastases and overall survival with this schedule have never been s...
Enregistré dans:
| Publié dans: | JAMA Oncol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Medical Association
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5824228/ https://ncbi.nlm.nih.gov/pubmed/28542671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.0278 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|